Warfarin Sensitivity (CYP2C9, CYP4F2, VKORC1)
Warfarin Sensitivity (CYP2C9 and VKORC1), 3 mutations is used for detection of single point polymorphism or gene variation of the *2 and *3 alleles of the CYP2C9 gene and of the VKORC1 gene used as an aid in the identification of patients at risk for increased warfarin sensitivity.
Warfarin is the most widely prescribed anti-clotting agent worldwide, used as a main therapy for thrombolytic disorders. Assessing the therapy of warfarin as a main anti-clotting agent is very important, as overdosing can result in life-threatening events, e.g., bleeding.
Warfarin is mainly metabolized in liver by CYP2C9, a member of the cytochrome P450 family and by the Vitamin K Epoxide Reductase Complex, Subunit 1gene (VKORC1), which is inhibited by warfarin. Additional Cytochrome P450 enzyme CYP4F2 genes may also predict sensitivity to warfarin.
Many allelic variants of CYP2C9 have been described in the literature, most of which encode dysfunctional or nonfunctional proteins. The two most common alleles of CYP2C9 that affect Warfarin metabolism are CYP2C9*2 (also known as R144C) and CYP2C9*3 (also known as I359L). Polymorphisms at these alleles produce defective CYP2C9 protein that exhibits reduced activity for metabolizing warfarin. Individuals who are heterozygous or homozygous variant for either CYP2C9*2 or CYP2C9*3 are generally more sensitive to standard doses of warfarin than similar individuals who lack the variant.
CYP4F2 metabolizes reduced vitamin K to hydroxyl-vitamin K1, thus removing it from the pathways involved in the activation of clotting factors impacted by warfarin. In individuals who self-identify as being of non-African ancestry, carriers of the CYP4F2*3 (C.1297G->A; rs2108622) variant may need a small (5%-10%) warfarin dosage increase to achieve therapeutic goals.
The VKORC1 gene, located on the short arm of human chromosome 16 (16p11.2), encodes the VKORC1 protein which plays an important role in metabolism of Vitamin K needed for clotting.
Warfarin inhibits VKORC1, reducing clotting efficiency. Many gene variations have been reported in the VKORC1 gene. The most common VKORC1 polymorphisms are 1173C>T and c.-1639G>A, which together with CYP2C9 gene mutations (*2 and *3) are estimated to account for 40-63 percent of the variability in therapeutic warfarin dose.
- Determining therapeutic strategy for warfarin therapeutic dosing
- As an aid in the identification of patients at risk for increased warfarin sensitivity
- Assessment of the therapeutic dosing for warfarin used for treatment of thrombolytic disorders
Results are usually reported as normal metabolizers (NM), intermediate metabolizers (IM), and poor metabolizers (PM). This varies, depending on the technology and the laboratory that performs the testing. The wild-type allele of the CYP2C9 gene is designated *CYP2C9*1. Homozygous wild-type individuals have a normal metabolizer phenotype (NM).
- Normal metabolizers (NM) have no gene variation, are normal metabolizers. This phenotype include two active CYP2C9 alleles
- Intermediate metabolizers (IM) contain one variant and one normal CYP2C9 allele. Therefore, activity of this enzyme is decreased and the phenotypes may require lower than average drug dose for optimal therapeutic response
- Poor metabolizers (PM) have two or more gene variants and the enzyme activity is significantly decreased. Phenotypes with these variants have increased risk of drug-induced side effects due to significant decreased enzyme activity
The most common poor metabolizer phenotypes have been identified as CYP2C9*2 and *CYP2C9*3, which differ from the normal CYP2C9*1 by a single nucleotide substitution, which leads to impaired enzyme activity. If genetic polymorphisms of CYP2C9 (*2, *3) are present, this would predict altered enzyme activity and address the potential effects of metabolized drugs. Change in the therapy should be executed.
Allele Frequency:
CYP2C9 *2, 0.08-0.13, 0.02-0.06, and less than 0.01
CYP2C9 *3, 0.06-0.10, less than 0.01, and 0.01-0.04
VKORC1 (c.-1639G>A), 0.42, 0.89, and 0.08 in Caucasian, Asian, and African-American populations, respectively. Other populations are less well characterized. The VKORC1 (c.-1639G>A) is in very strong linkage disequilibrium with the VKORC1 (1173C>T).
The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP2C9:
NSAIDs: diclofenac, ibuprofen, lornoxicam, meloxicam, S-naproxen→Nor, piroxicam, suprofen
Oral Hypoglycemic Agents: tolbutamide, glipizide
Angiotensin II Blockers: losartan, irbesartan
Sulfonylureas: glyburide, glibenclamide, glipizide, glimepiride, tolbutamide, amitriptyline, celecoxib, fluoxetine, fluvastatin, glyburide, nateglinide, phenytoin-4-OH2, rosiglitazone, tamoxifen, torsemide, S-warfarin
The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.
A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: fluconazole.
A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include: amiodarone, fenofibrate, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, probenicid, sertraline, sulfamethoxazole, sulfaphenazole, teniposide.
A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance such as voriconazole and zafirlukast.
Cytochrome P450 4F2 (CYP4F2) variant 3 (c.1297G>A) is abnormal metabolizer.
The combined genotype of all three enzymes can be used to help predict an individual's response to warfarin therapy. If no detectable variants are found in CYP2C9, a 1 allele is assigned.
CYP2C9 Genotype *1/*1: Normal Metabolizers
VKORC1 Genotype 1639G G/G : Low Warfarin Sensitivity
CYP4F2 *3 Genotype *1/*1: Normal Metabolizer
Whole Blood EDTA (Lavender), ACD (Yellow) or Heparin (Green).
Stability
- Ambient: 7 days
- Refrigerated: 7 days
- Frozen: 30 days
- Clin Pharmacokinet. 2008;47(9):565-94. [PMID: 18698879]
- Clin Pharmacol Ther. 2002; 72: 702-710. [PMID: 12496751]
- Pharmacogenetics J. 2005; 5: 262-270. [PMID: 15883587]
- NEJM. 2005; 352: 2285-2293. [PMID: 15930419]
- Thromb Res. 2007;120(1):1-10. [PMID: 17161452]
- Circulation. 2010; 121(4):512-8. [PMID: 20083681]
- N Engl J Med. 2009; 360(4):363-75. [PMID: 19106083]
- Pharmacogenomics. 2009; Nov;10(11):1799-817. [PMID: 19891556]
- Circulation. 2010; 121(4):512-8. [PMID: 20083681]
- N Engl J Med. 2009; 360(4):363-75. [PMID: 19106083]